FDA advisory panel narrowly approves Sarepta's Duchenne gene therapy for accelerated approval
TL;DR Summary
An FDA advisory committee voted 8-6 in favor of accelerated approval of Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy, known as SRP-9001, based on a surrogate endpoint for patients who are able to walk and have a confirmed mutation.
Topics:business#accelerated-approval#duchenne-muscular-dystrophy#fda#gene-therapy#healthcare#sarepta-therapeutics
- Breaking: FDA adcomm backs accelerated approval of Sarepta's Duchenne gene therapy in close vote Endpoints News
- Tracking the FDA advisory panel on Sarepta's gene therapy STAT
- US FDA advisers narrowly back Sarepta's Duchenne gene therapy for accelerated approval Reuters
- FDA Duchenne muscular dystrophy gene therapy : Shots - Health News NPR
- SRPT Stock: Split FDA Panel Votes In Favor Of Sarepta's Gene Therapy | Investor's Business Daily Investor's Business Daily
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
6 min
vs 7 min read
Condensed
97%
1,237 → 40 words
Want the full story? Read the original article
Read on Endpoints News